ondansetron has been researched along with Genetic Predisposition in 6 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Antiemetic treatment with tropisetron or ondansetron could be improved by adjustment for the CYP2D6 genotype; approximately 50 subjects would have to be genotyped to protect one patient from severe emesis." | 5.10 | Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. ( Bauer, S; Brockmöller, J; Kaiser, R; Papies, A; Possinger, K; Roots, I; Schelenz, C; Sezer, O; Tremblay, PB, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Johnson, BA | 2 |
| Seneviratne, C | 1 |
| Wang, XQ | 1 |
| Ait-Daoud, N | 2 |
| Li, MD | 1 |
| Thompson, MD | 1 |
| Kenna, GA | 1 |
| Gener, B | 1 |
| Burns, JM | 1 |
| Griffin, S | 1 |
| Boyer, EW | 1 |
| Kuehn, BM | 1 |
| Roache, JD | 1 |
| Zanca, NA | 1 |
| Velazquez, M | 1 |
| Kaiser, R | 1 |
| Sezer, O | 1 |
| Papies, A | 1 |
| Bauer, S | 1 |
| Schelenz, C | 1 |
| Tremblay, PB | 1 |
| Possinger, K | 1 |
| Roots, I | 1 |
| Brockmöller, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacological Treatment for Alcoholism[NCT00382642] | Phase 3 | 283 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Antagonism Research Between Antiemetics Agents (Droperidol, Dexametasone, Ondansetron) and Acetaminophen in Thyroidectomy's Post-operative Analgesia.[NCT01679093] | Phase 3 | 66 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ondansetron and Genetic Predisposition
| Article | Year |
|---|---|
Variation in the Serotonin Transporter Gene and Alcoholism: Risk and Response to Pharmacotherapy.
Topics: Alcoholism; Clinical Trials as Topic; Genetic Predisposition to Disease; Genetic Variation; Humans; | 2016 |
3 trials available for ondansetron and Genetic Predisposition
| Article | Year |
|---|---|
Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron.
Topics: Adult; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Drug M | 2013 |
Ondansetron reduces the craving of biologically predisposed alcoholics.
Topics: Adult; Alcoholism; Analysis of Variance; Behavior, Addictive; Chi-Square Distribution; Double-Blind | 2002 |
Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytochrome P-450 CYP2D6; Female; | 2002 |
2 other studies available for ondansetron and Genetic Predisposition
| Article | Year |
|---|---|
Administration of ondansetron is associated with lethal outcome.
Topics: Antiemetics; Child, Preschool; Diseases in Twins; Fatal Outcome; Genetic Predisposition to Disease; | 2010 |
Study suggests gene may predict success of therapies for alcohol dependence.
Topics: Alcoholism; Genetic Predisposition to Disease; Humans; Naltrexone; Narcotic Antagonists; Ondansetron | 2011 |